Quest Diagnostics Incorporated (DGX)
NYSE · Healthcare · Diagnostics & Research
$232.22−0.48%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $25.6B
- P/E (trailing)
- 24.6
- Forward P/E
- 19.3
- Dividend yield
- 1.5%
- 52-week range
- $171.18 – $248.84
- 52-week change
- +28.28%
- EPS (trailing)
- $9.42
- Analyst rating
- 2.1 Buy
- Next earnings
- Oct 22, 2026
Fiscal year to Dec 2025
- Revenue
- $11.0B (+11.78%)
- Net income
- $992M
- Operating margin
- 14.1%
- Diluted EPS
- $8.75
- Free cash flow
- $1.4B
From the company’s annual report on SEC EDGAR.
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals.
Headquarters: Secaucus, United States · 46,000 employees · questdiagnostics.com